Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomefloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | HPGD | P15428 | 5/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomefloxacin SCHEMBL29895425 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL133835 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL9226104 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL34609 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL29388501 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL34610 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL42052 | 0.97 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL8912235 | 0.97 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL42051 | 0.97 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 | |
| Lomefloxacin SCHEMBL30034879 | 0.97 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064476-A | Solid phase extraction-ultra-high performance liquid chromatography-tandem mass spectrometry rapid determination method for various antibiotics in human urine | 复旦大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-115337263-B | Lomefloxacin hydrochloride eye drops | 江苏汉晨药业有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-115337263-A | Lomefloxacin hydrochloride eye drops | 江苏汉晨药业有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| CN-106109484-B | A kind of anti-inflammatory analgetic micro-nano particle and metal spectacle frame coating prepared therefrom | 佛山市高明绿化纳新材料有限公司 | 2019-10-18 | — | — | CN | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| CN-106109484-A | A kind of anti-inflammatory analgetic micro-nano particle and metal spectacle frame coating prepared therefrom | 佛山市高明绿化纳新材料有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-103969383-B | The assay method of fluoroquinolone antibiotics in a kind of cosmetics | 中国检验检疫科学研究院 | 2016-08-24 | — | — | CN | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| CN-103969383-A | Method for testing fluoroquinolones antibiotics in cosmetics | CHINESE ACAD INSP & QUARANTINE | 2014-08-06 | — | — | CN | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | KDM4E 2866/4885HSD17B10 1061/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.